<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="or anti-inflammatory medications [7]. Although several approved drugs such as" exact="hydroxychloroquine" post="and investigational agents such as remdesivir have shown anti-viral"/>
 <result pre="(43, 16.2%). The top three subcategories of anti-malarial drugs were" exact="chloroquine" post="phosphate, hydroxychloroquine, and phosphoric chloroquine. The next observed interventions"/>
 <result pre="by order of frequency were anti-viral drugs (29, 10.9%), including" exact="ritonavir" post="plus lopinavir, favipiravir, azzedine, and baloxavir marboxil, followed by"/>
 <result pre="Anti-malarial drugs 43 (16.2) Chloroquine phosphate 30 Hydroxychloroquine 7 Phosphoric" exact="chloroquine" post="4 Chloroquine 2 Anti-viral drugs 29 (10.9) Ritonavir plus"/>
 <result pre="chloroquine 4 Chloroquine 2 Anti-viral drugs 29 (10.9) Ritonavir plus" exact="lopinavir" post="8 Recombinant interferon 4 Favipiravir 4 Azzedine 3 Baloxavir"/>
 <result pre="analyses. For example, only 200-patient randomized controlled trial showed that" exact="lopinavir" post="plus ritonavir had no treatment benefit beyond standard care"/>
 <result pre="example, only 200-patient randomized controlled trial showed that lopinavir plus" exact="ritonavir" post="had no treatment benefit beyond standard care against COVID-19,"/>
 <result pre="authorization for emergency cases [23]. However, current results demonstrate that" exact="hydroxychloroquine" post="[24] and lopinavir plus ritonavir [25] have no benefit"/>
 <result pre="cases [23]. However, current results demonstrate that hydroxychloroquine [24] and" exact="lopinavir" post="plus ritonavir [25] have no benefit for COVID-19 patients"/>
 <result pre="However, current results demonstrate that hydroxychloroquine [24] and lopinavir plus" exact="ritonavir" post="[25] have no benefit for COVID-19 patients in randomized"/>
 <result pre="PMCID: PMCPMC7078228. doi: 10.1038/s41421-020-0156-032194981 9WangM, CaoR, ZhangL, et al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
 <result pre="the submitted work.32409561 25HungIF-N, LungK-C, TsoEY-K, et al.Triple combination of" exact="interferon beta-1b," post="lopinavir–ritonavir, and ribavirin in the treatment of patients admitted"/>
 <result pre="LungK-C, TsoEY-K, et al.Triple combination of interferon beta-1b, lopinavir–ritonavir, and" exact="ribavirin" post="in the treatment of patients admitted to hospital with"/>
</results>
